DCM
DAFNA Capital Management Portfolio holdings
AUM
$362M
This Quarter Return
+9.26%
1 Year Return
-0.48%
3 Year Return
+117.01%
5 Year Return
+181.93%
10 Year Return
+1,483.26%
AUM
$398M
AUM Growth
+$398M
(+5.5%)
Cap. Flow
+$11.1M
Cap. Flow
% of AUM
2.78%
Top 10 Holdings %
Top 10 Hldgs %
51.36%
Holding
92
New
12
Increased
23
Reduced
18
Closed
5
Top Buys
| 1 |
Adicet Bio
ACET
|
$6.24M |
| 2 |
Syndax Pharmaceuticals
SNDX
|
$4.72M |
| 3 |
CBAY
Cymabay Therapeutics
CBAY
|
$4.27M |
| 4 |
Axogen
AXGN
|
$3.11M |
| 5 |
MEI Pharma
MEIP
|
$3M |
Top Sells
| 1 |
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
|
$11.8M |
| 2 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
$4.13M |
| 3 |
KDMN
Kadmon Holdings, Inc.
KDMN
|
$2.74M |
| 4 |
AFMD
Affimed
AFMD
|
$2.17M |
| 5 |
Galapagos
GLPG
|
$1.93M |
Sector Composition
| 1 | Healthcare | 94.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Stereotaxis
STXS
$261M
| $84.8M | 21.33% | 13,680,554 | – | – |
|
|
BPMC
2
DELISTED
Blueprint Medicines
BPMC
| $22.2M | 5.57% | 206,911 | – | – |
|
3
Fate Therapeutics
FATE
$120M
| $21.8M | 5.48% | 372,160 +27,800 | +8% | +$1.63M |
|
|
4
Adicet Bio
ACET
$59.9M
| $12.8M | 3.22% | 733,172 +356,891 | +95% | +$6.24M |
|
5
Xenon Pharmaceuticals
XENE
$2.98B
| $12.6M | 3.16% | 402,667 -3,868 | -1% | -$121K |
|
|
ARNA
6
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $11.1M | 2.8% | 119,615 | – | – |
|
7
IDEAYA Biosciences
IDYA
$2.15B
| $10.9M | 2.73% | 460,061 | – | – |
|
8
DexCom
DXCM
$29.5B
| $9.74M | 2.45% | 18,138 -3,000 | -14% | -$1.61M |
|
|
KRTX
9
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $9.49M | 2.39% | 72,423 -2,162 | -3% | -$283K |
|
10
Nurix Therapeutics
NRIX
$714M
| $8.87M | 2.23% | 306,320 | – | – |
|
|
MORF
11
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $8.6M | 2.16% | 181,467 | – | – |
|
|
BHVN
12
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $8.01M | 2.01% | 58,100 -30,000 | -34% | -$4.13M |
|
|
SAGE
13
DELISTED
Sage Therapeutics
SAGE
| $7.67M | 1.93% | 180,306 | – | – |
|
14
Merus
MRUS
$4.98B
| $7.19M | 1.81% | 226,089 +94,140 | +71% | +$2.99M |
|
15
Neurocrine Biosciences
NBIX
$13.8B
| $7.13M | 1.79% | 83,655 -1,000 | -1% | -$85.2K |
|
|
16
Syndax Pharmaceuticals
SNDX
$1.41B
| $6.49M | 1.63% | 296,535 +215,833 | +267% | +$4.72M |
|
17
iShares Biotechnology ETF
IBB
$5.6B
| $6.24M | 1.57% | 40,900 | – | – |
|
18
Cytokinetics
CYTK
$4.23B
| $6.11M | 1.54% | 134,094 -40,906 | -23% | -$1.86M |
|
|
CBAY
19
DELISTED
Cymabay Therapeutics
CBAY
| $6.04M | 1.52% | 1,787,569 +1,263,283 | +241% | +$4.27M |
|
|
CSII
20
DELISTED
Cardiovascular Systems, Inc.
CSII
| $5.39M | 1.36% | 286,988 +93,247 | +48% | +$1.75M |
|
21
Revolution Medicines
RVMD
$7.1B
| $5.34M | 1.34% | 212,231 +2,500 | +1% | +$62.9K |
|
22
AtriCure
ATRC
$1.84B
| $5.01M | 1.26% | 72,029 | – | – |
|
23
Arcus Biosciences
RCUS
$1.13B
| $4.74M | 1.19% | 117,200 -6,500 | -5% | -$263K |
|
|
24
MEI Pharma
MEIP
$160M
| $4.71M | 1.18% | 1,764,846 +1,123,846 | +175% | +$3M |
|
|
ISEE
25
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $4.61M | 1.16% | 275,976 +59,625 | +28% | +$997K |
|